Table 1 Baseline characteristics of study patients receiving montelukast and placebo (n = 100)
Number | Montelukast | Placebo |
|---|---|---|
50 | 50 | |
Age in years (SD) | 50.50 ± 18.26 | 52.68 ± 18.86 |
Male: Female (n) | 7:43 | 14:36 |
Asthma history | ||
a. Past history of sudden severe exacerbations | 22 (44%) | 22 (44%) |
b. > 2 admissions | 17 (34%) | 11 (22%) |
c. ICU admissions | 03 (06%) | 06 (12%) |
d. Prior intubation | 01 (02%) | 04 (08%) |
Family history of Asthma | 30 (60%) | 27 (54%) |
Medication history | ||
a) Fluticasone 250 mcg + Salmeterol 25 mcg | 24 (48%) | 25 (50%) |
b) Oral Theophylline | 07 (14%) | 11 (22%) |
c) Inhaled anti-cholinergic | 01 (02%) | 02 (04%) |
Precipitating factors | ||
a) Infection | 23 (46%) | 22 (44%) |
b) Weather change | 27 (54%) | 24 (48%) |
c) Non-compliance to drugs | 01 (02%) | 01 (02%) |
d) Allergen exposure | 07 (14%) | 10 (20%) |
f) None | 04 (07%) | 02 (04%) |
Smoking status | ||
a) Non-smoker | 47 (94%) | 42 (84%) |
b) Current smoker | 02 (04%) | 03 (06%) |
c) Ex-smoker | 01 (02%) | 05 (10%) |
Additional therapy | ||
a) IV aminophylline | 03 (06%) | 02 (04%) |
b) IV magnesium sulphate | 16 (32%) | 15 (30%) |
c) Oral theophylline | 10 (20%) | 16 (32%) |